Background: The prevalence of heart failure with mildly reduced or preserved ejection
fraction markedly increases with age, with older individuals disproportionately facing excess …

Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …

Aim: To estimate the projected effectiveness of dapagliflozin in subjects with heart failure
(HF) with reduced ejection fraction in clinical practice in Spain. Materials & methods: This …

Aims The effects of adding a sodium–glucose cotransporter 2 (SGLT2) inhibitor to a
mineralocorticoid receptor antagonist (MRA) or an angiotensin receptor–neprilysin inhibitor …

Aims Obesity is common and associated with unique phenotypic features in heart failure
with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of …

Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly
reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse …

Background: Patients with heart failure (HF) and reduced ejection fraction will experience
multiple hospitalizations for heart failure during the course of their disease. We assessed the …

Background: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–
Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor …

Aims Patients with heart failure experience a high burden of symptoms and physical
limitations, and poor quality of life. Dapagliflozin reduces heart failure hospitalization and …

Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of
symptoms and functional limitations, and have a poor quality of life. By targeting …